Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients
- PMID: 20935553
- DOI: 10.1097/QAD.0b013e3283400088
Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients
Abstract
Objective: HIV-1-infected patients with lipodystrophy show insulin resistance, dyslipidemia and other signs of metabolic syndrome. Fibroblast growth factor-21 (FGF21) is a novel metabolic regulator that has been suggested to exert beneficial effects on metabolic homeostasis and insulin sensitivity. Our goal was to determine the relationship between FGF21 levels and metabolic alterations in these patients.
Research design and methods: Serum FGF21 levels were analyzed in 179 individuals belonging to four groups: HIV-1-infected, antiretroviral-treated patients that have developed lipodystrophy (n = 59); HIV-1-infected, antiretroviral-treated patients without lipodystrophy (n = 45); untreated (naive) HIV-1-infected patients (n = 41); and healthy control individuals (n = 34). Serum FGF21 levels were correlated with parameters indicative of altered fat distribution, metabolic and cardiovascular risk, and in relation to HIV-1 infection and antiretroviral treatment regimens.
Results: Serum FGF21 levels were increased in all HIV-1-infected patients, but the increases were most marked in those with lipodystrophy. FGF21 levels showed a strong positive correlation with indicators of lipodystrophy (trunk/apendicular fat ratio, waist-to-hip ratio), insulin resistance (fasting glucose, HOMA-R), dyslipidemia (low-density lipoprotein cholesterol), and liver injury (γ-glutamyltransferase).
Conclusions: FGF21 levels are increased in HIV-1-infected patients, especially in those with lipodystrophy, and this increase is closely associated with insulin resistance, metabolic syndrome and makers of liver damage. Further research will be required to determine whether the increase in FGF21 levels is caused by a compensatory response or resistance to FGF21, and to establish the potential of FGF21 as a biomarker of altered metabolism in HIV-1-infected, antiretroviral-treated patients.
Similar articles
-
Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.AIDS. 2006 Feb 14;20(3):387-95. doi: 10.1097/01.aids.0000206503.01536.11. AIDS. 2006. PMID: 16439872
-
Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy.Antivir Ther. 2007;12(2):195-203. Antivir Ther. 2007. PMID: 17503662
-
Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease.HIV Med. 2009 Jan;10(1):28-34. doi: 10.1111/j.1468-1293.2008.00649.x. HIV Med. 2009. PMID: 19125962
-
[Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].Rev Med Chir Soc Med Nat Iasi. 2006 Jul-Sep;110(3):521-5. Rev Med Chir Soc Med Nat Iasi. 2006. PMID: 17571539 Review. Romanian.
-
Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.AIDS Read. 2003 Dec;13(12 Suppl):S5-13. AIDS Read. 2003. PMID: 14959694 Review.
Cited by
-
Metabolic, Mitochondrial, and Inflammatory Effects of Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate in Asymptomatic Antiretroviral-Naïve People with HIV.Int J Mol Sci. 2024 Aug 1;25(15):8418. doi: 10.3390/ijms25158418. Int J Mol Sci. 2024. PMID: 39125986 Free PMC article.
-
Metabolic and inflammatory perturbation of diabetes associated gut dysbiosis in people living with and without HIV infection.Genome Med. 2024 Apr 20;16(1):59. doi: 10.1186/s13073-024-01336-1. Genome Med. 2024. PMID: 38643166 Free PMC article.
-
Adipose Tissue Dysfunction and Energy Balance Paradigms in People Living With HIV.Endocr Rev. 2024 Mar 4;45(2):190-209. doi: 10.1210/endrev/bnad028. Endocr Rev. 2024. PMID: 37556371 Free PMC article. Review.
-
Heightened levels of plasma growth differentiation factor 15 in men living with HIV.Physiol Rep. 2022 May;10(9):e15293. doi: 10.14814/phy2.15293. Physiol Rep. 2022. PMID: 35510313 Free PMC article.
-
Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.Front Endocrinol (Lausanne). 2022 Mar 9;13:814209. doi: 10.3389/fendo.2022.814209. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35355551 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical